Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...
Please provide your email address to receive an email when new articles are posted on . APT-1011, a novel fluticasone orally disintegrating tablet, effectively induced histologic response, improved ...
Objective: To compare the flavour and taste preferences of two acid-inhibitory therapies in children. Subjects and Setting: 104 (52 male and 52 female) healthy children aged 6-11 years participated in ...
MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...
A recently filed patent (Publication Number: US20230263735A1) describes a film-coated tablet with specific compositions and properties. The tablet consists of a core tablet coated with two film layers ...
- DARTISLA ODT is available as a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer - First and only orally ...
Rizatriptan (as benzoate) 10mg; orally-disintegrating tabs; peppermint flavor; contains phenylalanine. Maxalt-MLT Orally Disintegrating Tablets, 10 mg, are white to off-white, round lyophilized orally ...
RALEIGH, NC, September 8, 2009 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV TM ODT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results